Chronic myeloid leukemia: First-line drug of choice

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) revolutionized chronic myeloid leukemia (CML) treatment.
• Imatinib was the first TKI, serving as the standard of care for over a decade.
• Second-generation TKIs (dasatinib, nilotinib) offer faster, deeper responses than imatinib.

Purpose of the Study:

• To review frontline treatment options for chronic myeloid leukemia (CML).
• To guide clinicians in selecting the optimal upfront TKI therapy for CML patients.
• To emphasize early recognition of noncompliance or treatment failure for improved outcomes.

Main Methods:

• Review of clinical trial data and treatment guidelines for CML.
• Analysis of efficacy, safety, and tolerability profiles of frontline TKIs.
• Discussion of patient-specific factors influencing TKI selection.

Main Results:

• Second-generation TKIs provide quicker and more profound responses compared to imatinib.
• No significant survival advantage has been demonstrated for second-generation TKIs over imatinib.
• Expected survival for managed CML patients approaches that of the general population.

Conclusions:

• Frontline TKI selection for CML requires careful consideration of patient comorbidities, TKI side effect profiles, and cost.
• Prompt identification and management of noncompliance or treatment failure are crucial for achieving optimal CML response.
• Personalized TKI selection is key to maximizing treatment success in chronic myeloid leukemia.